|Bid||234.70 x N/A|
|Ask||236.60 x N/A|
|Day's Range||234.70 - 234.70|
|52 Week Range||156.53 - 264.60|
|Beta (3Y Monthly)||0.78|
|PE Ratio (TTM)||48.70|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The charts of IDEXX Laboratories and Zoetis have weakened recently, and while the Westminster Dog Show is not for a few more months, it looks like these stocks could be going to the dogs. In this daily bar chart of IDXX, below, we can see that prices traded sideways since June with buyers showing up around $260 until today.
Fido and Fluffy have health concerns, too, and animal health companies like Zoetis and Idexx Laboratories are in hot pursuit of the rapidly developing pet health market.
Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after […]
This is the second of two stories that Investopedia is devoting to a report from Goldman Sachs recommending stocks with longterm stable profit growth.
Shares of medical stocks Idexx Laboratories and Masimo approached breakouts Friday as Wall Street enjoyed a third day of gains. Both stocks are now in the process of forming flat bases.
IDEXX Laboratories and Zoetis Inc. appear ready to trade higher, offering stable opportunities as the dog-eat-dog trade war lingers on.
For his Executive Decision segment of "Mad Money" Wednesday our own Jim Cramer sat down with Jonathan Ayers, chairman, president and CEO of Idexx Laboratories Inc. IDXX, an animal health company. For those pets who do see their vet, however, diagnostics from Idexx are becoming an integral part of their care. Ayers said Idexx continues to innovate, which helps it see strong organic growth and increased operating margins.
"[Millennials] are more likely to go to the vet more frequently and more willing to listen to an advanced standard of care," CEO Jonathan Ayers says. About 42% of millennials think their pets have special health needs — more than double the percentage of the baby boomer generation, he said. Idexx Laboratories IDXX has room to grow in providing preventative care for pets, CEO Jonathan Ayers told CNBC Wednesday.
Chairman, President & CEO of Idexx Laboratories Inc (NASDAQ:IDXX) Jonathan W Ayers sold 28,000 shares of IDXX on 05/03/2019 at an average price of $249.02 a share.
On a per-share basis, the Westbrook, Maine-based company said it had net income of $1.17. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
IDEXX Laboratories Inc develops, manufactures and distributes products and provide services for companion animal veterinary, livestock and poultry, dairy and water testing markets. IDEXX Laboratories Inc had annual average EBITDA growth of 13.10% over the past ten years. GuruFocus rated IDEXX Laboratories Inc the business predictability rank of 5-star.
Chairman, President & CEO of Idexx Laboratories Inc (NASDAQ:IDXX) Jonathan W Ayers sold 47,714 shares of IDXX on 02/07/2019 at an average price of $206.53 a share.
Positive news about consumer spending helped send the company's share price up last month heading into its fourth-quarter earnings report in early February.
The Westbrook, Maine-based company said it had net income of 98 cents per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...